Table 1.

Table 1a Immunosuppressive protocols
Immunosuppressants	Immunosuppressive protocols
		Multiagent	Light
Thymoglobulin (intravenous)		2.5 mg/kg (day −2), 1.5–2.5 mg/kg (days 0–7), targeting lymph count <0.5 × 109	25 mg/kg, once (day –1)
Tacrolimus (per os)	Dose	4–5 mg/kg twice daily (from day 0)	3–4 mg/kg twice daily (from day 0)
	Trough level	20–30 ng/ml	10–15 ng/ml
Methylprednisolone (intravenous)		1.0 mg/kg (days 0–2), tapered by 0.05 mg/kg/d to 0.2 mg/kg	1.0 g, once (day –1)
MMF(per os)		25–30 mg/kg twice daily (from day 8)	None
Cobra venom factor (intravenous)		0.05 mg/kg (day –2), 0.02 mg/kg every 36 h (days 1–14)	None

Table 1b Immunosuppressive protocol, antibody levels, survival, cause of death and terminal graft histology for individual animals
	Preformed antibodies to non-Gal antigensa			Induced antibodies to non-Gal antigensa
Animal ID	Protocol	IgG	IgM	IgG	IgM	Survival (d)	Cause of death	Graft histology
20-02	Light	2.9	1.1	19.5	1.6	8	Renal failure	AHXR III
64-03	Light	3.4	1.0	88.1	2.5	11	Renal failure	AHXR III
67-03	Lightb	2.9	1.1	8.6	1.1	10	Sepsis	AHXR I
19-02	Multiagent	5.1	1.0	30	1.5	16	Renal failure	AHXR III
66-03	Multiagentc	2.7	1.1	7.2	3.0	13	Renal failure	AHXR III
65-03	Multiagentd	3.4	1.3	6.8	1.2	9	Gastrointestinal bleeding	ACXR I, AHXR I

^aAntibody data presented are the ratio of relative mean fluorescence (RMF); underline indicates high values of induced antibodies to non-Gal antigens.

^bThis recipient received 50 mg/kg ATG for induction therapy.

^cThis recipient received 21 d of desensitization pretreatment (plasmapheresis and intravenous immunoglobulin five times, two doses of Rituxan and daily tacrolimus and MMF).

^dThis recipient received cyclophosphamide instead of ATG as induction therapy with splenectomy and Rituxan. MMF, mycophenolate mofetil; ACXR, acute cellular xenograft rejection.